Insight Molecular Diagnostics Inc IMDX
$4.34 $0.04 (0.93%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
IMDX Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Insight Molecular Diagnostics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Insight Molecular Diagnostics Inc. Stock Analysis IMDX
United States Health Care Micro Cap Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Nashville, Tennessee and currently employs 55 full-time employees. The company went IPO on 2015-12-30. The firm's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The firm's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.
Insight Molecular Diagnostics Inc (IMDX) Chart
Financial Metrics & Statements of Insight Molecular Diagnostics Inc (IMDX)
FAQ's for Insight Molecular Diagnostics Inc (IMDX)
- As of August 2026, Insight Molecular Diagnostics Inc IMDX is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Insight Molecular Diagnostics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Insight Molecular Diagnostics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Insight Molecular Diagnostics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Insight Molecular Diagnostics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Insight Molecular Diagnostics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Insight Molecular Diagnostics Inc (IMDX)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
